Nivasorexant

A medication used for the treatment of insomnia

Nivasorexant
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Nivasorexant is a medication that is primarily used for the treatment of insomnia. It belongs to a class of drugs known as orexin receptor antagonists, which work by blocking the action of orexin, a neurotransmitter involved in the regulation of the sleep-wake cycle.

Mechanism of Action

Nivasorexant functions as a dual orexin receptor antagonist (DORA). It selectively inhibits the binding of orexin A and orexin B to their receptors, OX1R and OX2R. By blocking these receptors, nivasorexant reduces the wake-promoting action of orexin, thereby facilitating the onset and maintenance of sleep.

Pharmacokinetics

Nivasorexant is administered orally and is absorbed into the bloodstream where it reaches peak plasma concentrations within a few hours. The drug is metabolized primarily in the liver and is excreted through the kidneys. The half-life of nivasorexant allows for once-daily dosing, typically administered in the evening before bedtime.

Clinical Use

Nivasorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It is particularly useful for patients who have not responded adequately to other forms of treatment, such as cognitive behavioral therapy for insomnia or other pharmacological agents.

Side Effects

Common side effects of nivasorexant include drowsiness, headache, and dizziness. Some patients may experience more severe side effects such as sleep paralysis, hypnagogic hallucinations, or complex sleep behaviors like sleepwalking. It is important for patients to be monitored for these effects, especially during the initial phase of treatment.

Contraindications

Nivasorexant is contraindicated in patients with narcolepsy due to its mechanism of action on the orexin system. Caution is advised in patients with severe hepatic impairment, as this may affect the drug's metabolism and clearance.

Related Pages

• Insomnia
• Orexin receptor antagonist
• Sleep disorder
• Pharmacology